( October 5, 2026, 06:50 GMT | Official Statement) -- MLex Summary: Shionogi, a publicly listed Japanese pharmaceutical company, said Monday that it will acquire all shares in US pharmaceutical company IntraBio for $2 billion, adding rare-disease drug Aqneursa and its global intellectual property and commercialization rights to its portfolio. The acquisition, expected to close between November and December, is subject to applicable competition-law waiting periods as well as regulatory approvals and clearances in relevant countries.Statement is attached....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.